Given these clinical needs, particularly for the incurable, aggressive, and rare entities of γδ T-NHL and NKTCLs, we aimed to design an HDAC6 inhibitor with drug-like properties, explored here via medicinal chemistry, X-ray crystallography studies, pharmacological and biochemical methodologies. The gene discussed is HDAC6; the disease is non-Hodgkin lymphoma.